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Background: To evaluate the palliative effect of endobronchial brachy-
therapy (EBB) for patients who previously received the external beam 
radiotherapy (EBRT).
Methods: From July 1992 to May 2003, 29 patients with recurrent or 
persistent non-small cell lung cancer (NSCLC) were treated with pal-
liative EBB at our institute. EBB consisted of 3 fractions (once a week) 
of 5 Gy, delivered 1 cm from source using the high dose rate remote 
afterloader. The symptomatic response rates were assessed. And the 
factors, such as age, performance status, previous EBRT dose, elapsed 
time from EBRT to EBB, the extent of endobronchial tumor, and the 
degree of occlusion were compared between symptomatic responders 
and non-responders.
Results: Median age was 62 years (46~71 years). Eastern Coopera-
tive Oncology Group (ECOG) performance scale 1, 2, 3 was 13, 15, 1 
patient respectively. Total dose of previous EBRT was median 54 Gy 
(45~63 Gy) with daily dose of median 2.5 Gy (1.8~3 Gy). Elapsed time 
from EBRT to EBB was median 7 months (1~102 months). 22 patients 
complained of 2 or more symptoms caused by endobronchial tumor. 
Type of symptoms were cough (n=22), dyspnea (n=16), hemoptysis 
(n=11), obstructive pneumonia (n=3) and chest pain (n=1). The extent 
of tumor was to the distal trachea in 15 and to the main bronchus or 
lobar bronchus in 14 patients. 19 patients (66%) had nearly total (more 
than three quarter of the lumen) or total occlusion by tumor at ﬁrst 
EBB. Median follow up was 6 months (1~34 months). Only 2 patients 
could not complete the scheduled treatment. The overall symptomatic 
response rates were 51% (27/53). Response rates as to the type of 
symptoms were 41% for cough, 50% for dyspnea, 82% for hemop-
tysis, and 33% for obstructive pneumonia. Of the type of symptoms, 
hemoptysis was better relieved than cough (Fisher’s exact test, p<0.05). 
The median time to symptom relapse was 6 months (3~31 months). 17 
(59%) patients (symptomatic responders) were relieved from all or part 
of symptoms after or during EBB and 12 (41%) patients (non-respond-
ers) were not relieved from their symptoms at all. The symptomatic 
responders had better performance status (ECOG 1) or more tumor 
extent to distal trachea than non-responders. And the difference was 
signiﬁcant statistically (Fisher’s exact test, p<0.05). Bronchopleural 
ﬁstula was developed in 2 patients (7%) and one of them died of the 
complication. 
Conclusions: The overall symptomatic response rates were 51% and 
the response maintained for 6 months. Palliative EBB, even though 
EBRT was given previously, could be effective especially if a patient 
has the symptom, such as hemoptysis caused by distal tracheal lesion.
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A phase ii study to determine the efficacy of Tarceva (Erlotinib 
Hydrochloride) with concurrent whole brain radiation therapy in 
patients with brain metastases from non-small cell lung cancer
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Purpose: Brain metastatic disease continues to be a leading cause of 
death in patients (pts) with non-small cell lung cancer (NSCLC). De-
spite treatment advances such as stereotactic radiosurgery, Motexaﬁn 
Gadolinium and RSR-13, survival for pts with brain metastases remains 
largely unchanged. Encouraged by the synergistic priorities of tyrosine 
kinase inhibitors (TKI) and radiation, we developed a clinical trial of 
concurrent Tarceva (OSI Pharmaceuticals, Boulder CO) and WBRT for 
pts with NSCLC brain metastatic disease. We did not select for EGFR 
mutations as most pts did not undergo craniotomy. 
Methods: This single institution phase II study was opened in Febru-
ary of 2006 with a goal of enrolling 33 pts with brain metastases from 
NSCLC. Pts were treated with Tarceva 150mg PO daily. On day seven 
of treatment external beam radiation was initiated using opposed lateral 
to deliver 3000cGy in ten fractions. Following radiation, pts remained 
on Tarceva until they had documentation of disease progression, de-
veloped signiﬁcant toxicity or were started on systemic therapy. Dose 
reduction was allowed; however, all patients had to remain on Tarceva 
until completion of radiation to remain evaluable.
Results: For 10 pts enrolled thus far, all have completed Tarceva and 
WBRT. With a median follow-up of 8 months, 50% of the patients 
remain alive at time of analysis. One patient required dose reduction 
secondary to grade 2 rash. Two patients have experienced early grade 
three toxicity, including diarrhea and pruritus. One pt developed a late 
grade 3 neurocognitive toxicity at 8 months after treatment; this pt 
is the longest survivor at 12 months. At the time of analysis, 50% of 
patients remain alive; the median expected survival based on RPA (Re-
cursive Partitioning Analysis) is 4.2 months, while the actuarial median 
survival for our pts thus far has been 6.3 months. 
Discussion: Brain metastases from NSCLC continues to confer a very 
poor prognosis that has changed little over the last few decades. By 
combining the EGFR inhibitory mechanism of Tarceva along with con-
current radiation therapy we hope to improve progression free survival, 
while limiting neurocognitive impairment. Data from the ﬁrst 10 pts 
show that concurrent Tarceva with WBRT is feasible, with a low fre-
quency of early adverse events consistent with EGFR/TKI safety data. 
We noted one late toxicity of neurocognitive deﬁcit; we will be moni-
toring for further late toxicities, compared to what has been reported for 
long-term survivors of WBRT. In terms of survival, these preliminary 
results appear encouraging in comparison with historical controls, with 
a median increase of 2.1 months. Accrual to the trial continues. 
